LBA10 Amivantamab Plus Lazertinib Vs Osimertinib As First-Line Treatment among Asian Patients with EGFR-mutated, Advanced Non-Small Cell Lung Cancer (NSCLC): MARIPOSA Subgroup Analysis

S. Lu,B. C. Cho,J-S. Lee,S-H. Lee,P. Danchaivijitr,B. Liu,A. Alip,H. Xiong,S. H. How,G-C. Chang,J. C-H. Yang,H. Yoshioka,K. Xia,M. Martinez,J. M. Bauml,S. Sethi,H. Hayashi

DOI: https://doi.org/10.1016/j.annonc.2023.10.582

IF: 51.769

2023-01-01

Annals of Oncology

Abstract:Amivantamab (ami) is a bispecific antibody targeting EGFR and MET with immune-directing activity. Lazertinib (laz) is an oral, central nervous system (CNS)-penetrant, 3rd-generation EGFR tyrosine kinase inhibitor. In the global, phase 3, randomized, controlled MARIPOSA study (NCT04487080) ami-laz significantly improved progression-free survival (PFS) vs osimertinib (osi) in patients (pts) with previously untreated, EGFR-mutated, advanced NSCLC. The incidence of EGFR mutations is higher among Asian pts than other races. Thus, we evaluated the efficacy and safety of ami-laz vs osi in Asian pts based on the MARIPOSA trial. Pts were randomized 2:2:1 to receive ami-laz, osi, or laz. The primary endpoint was PFS based on blinded independent central review per RECIST v1.1. Secondary endpoints included objective response rate (ORR), duration of response (DoR), and safety. Of 1074 total randomized pts, 629 were Asian, with 250/429 and 251/429 randomized to the ami-laz and osi arms, respectively. Among Asian pts, median age was 63 years, 61%/57% female, and 44%/43% had a history of brain metastases for ami-laz/osi. At a median follow-up of 22.5 mo, ami-laz showed a 35% reduction in the risk of disease progression or death vs osi for Asian pts (hazard ratio [HR], 0.65; 95% confidence interval [CI], 0.50–0.83; P<0.001), with a median PFS of 27.5 vs 18.3 mo, which was comparable to the overall population. ORR was 88% (95% CI, 84–92) for ami-laz vs 85% (95% CI, 80–90) for osi (odds ratio, 1.29; 95% CI, 0.76–2.17). Median DoR among confirmed responders was 26.1 mo for ami-laz vs 17.5 mo for osi. Adverse event (AE) rates in Asian pts were similar to the overall MARIPOSA population. EGFR- and MET-related AEs were higher for ami-laz except diarrhea, which was higher for osi. VTEs were increased for ami-laz, but events were mostly grade 1-2 (no grade 4-5 events), occurred in the first 4 months of treatment, and were effectively managed with anticoagulants. ILD rates were low and similar across arms. Ami-laz demonstrated superior PFS vs osi in Asian pts with a tolerable safety profile. These results were consistent with those of the overall population.